Day: April 27, 2020

FORT WORTH, Texas, April 27, 2020 (GLOBE NEWSWIRE) — RANGE RESOURCES CORPORATION (NYSE: RRC) today announced that first quarter 2020 production averaged approximately 2,294 Mmcfe per day.  Range continues to expect 2020 production to average approximately 2.3 Bcfe per day, including an expected exit rate of approximately 2.3 Bcfe per day.The following table details Range’s average production and realized pricing for first quarter 2020:(a) Numbers may not add due to rounding.Range’s first quarter 2020 realized NGL price, before hedges, was $14.87 per barrel. This represents a $1.30 per barrel premium to the Mont Belvieu-equivalent barrel, which is at the upper end of Range’s 2020 guidance of $0.50 to $1.50 per barrel premium.  Range continues to see positive premiums to Mont Belvieu from NGL exports out of Marcus Hook, as lower international...

BERKELEY, Calif., and VANCOUVER, British Columbia, April 27, 2020 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining the development and use of novel therapeutics (i.e. multi-specific binding reagents) that activate immune cells to selectively destroy the cancer cells or to selectively block cancer cells from inactivating immune cells.The patent application, entitled “METHODS FOR INDUCING AND ENHANCING ANTI-CANCER IMMUNE RESPONSES USING NOVEL MOLECULAR CONSTRUCTS”, outlines the development and use of multi-specific binding reagents that simultaneously bind...

SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed, refractory multiple myeloma (RRMM). HPN217 is being developed under a global license and option agreement with AbbVie Inc. (NYSE:ABBV) and dosing of the first patient in a clinical trial has triggered a $50 million milestone payment to Harpoon. HPN217 targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma calls. HPN217 is Harpoon’s third product candidate to enter the clinic and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC™) platform designed...

WINNIPEG, Manitoba, April 27, 2020 (GLOBE NEWSWIRE) — People Corporation (the “Company”) (TSX Venture: PEO) today announced financial results for the quarter ended February 29, 2020.Laurie Goldberg, Executive Chairman and Chief Executive Officer commented, “People Corporation made solid strategic and financial progress in the second quarter of 2020. Steady execution of our strategy generated revenue growth of 45.5%, and growth in Adjusted EBITDA, of 52.3% compared to the same period last year. Delivering the Company’s unique value proposition for plan sponsors and their members, our team drove organic revenue growth of 15.6% in Q2.  We continue to see substantial opportunity to further leverage our national platform, capitalize on our growing scale and national distribution footprint, and to consistently evolve our product...

PUNAMUSTA MEDIA OYJ PÖRSSITIEDOTE 27.4.2020 KLO 13.30LIIKEVAIHDON KASVU JATKUI Q1:LLA VAHVANA KORONAVIRUKSEEN SAAKKA                     PunaMusta Media Oyj julkistaa liiketoimintakatsauksen, jossa esitetään yhtiön taloudellista kehitystä koskevat keskeiset tiedot. Liiketoimintakatsauksen luvut ovat tilintarkastamattomia.TAMMI-MAALISKUU 2020 LYHYESTI– Konsernin liikevaihto kasvoi 6,7 % ja oli 27,3 miljoonaa euroa (25,6 miljoonaa euroa).– Käyttökate oli 1,6 (2,3) miljoonaa euroa– Liiketulos oli -0,6 (0,5) miljoonaa euroa ja tulos ennen veroja -2,9 (1,8) miljoonaa euroa. – Liiketoiminnan nettorahavirta oli 4,8 (3,7) miljoonaa euroa.– Omavaraisuusaste oli 40,9 % (49,0 %).– Sijoitetun pääoman tuotto ennen veroja oli -3,7 % (2,8 %).– Oman pääoman tuotto verojen jälkeen oli -6,7 % (3,0 %).– Laimentamaton...

Talenom Oyj, pörssitiedote 27.4.2020 kello 13:30Talenom Oyj:n liiketoimintakatsaus tammi­–maaliskuu 2020 (tilintarkastamaton): Liikevaihto kasvoi 17 % ja liikevoitto parani 8 %  –  ensimmäinen vuosineljännes tavoitteiden mukainen

Talenom Plc, Stock exchange release, 27 April 2020 at 13:30Talenom Plc Business Review January–March 2020 (unaudited): Net sales grew by 17% and operating profit improved by 8% – first quarter in line with objectives